24/7 Market News- Kraig Labs Emerges as Spider Silk Trailblazer After Decades of Global Failures, Kraig Poised to Deliver First High-Performance Recombinant Breakthrough November 10, 2025 08:35 ET | Source: 24/7 Market News and Kraig Labs
DENVER, Nov. 10, 2025 (GLOBE NEWSWIRE) -- 247marketnews.com, a pioneer in digital media dedicated to the swift distribution of financial market news and information, reports that, after decades of scientific ambition and hundreds of millions of dollars invested worldwide, Kraig Biocraft Laboratories (OTCQB: KBLB), the undisputed global leader in the development and commercialization of spider silk, appears to be on the verge of achieving what no other company or country has been able to accomplish: the commercial delivery of high-performance recombinant spider silk.
In the opinion of 24/7 Market News, Kraig Labs’ imminent shipments of spider silk fiber and fabric samples to fashion and performance textile partners mark a historic turning point in one of biotechnology’s most elusive pursuits, a race that has spanned continents, companies, and generations of research.
A Global Quest with Multi-Billion-Dollar Backing
From DuPont and BASF abandoning serious R&D efforts, to ambitious national projects from numerous governments, research institutions, and biotech startups that poured resources into the quest for scalable spider silk has been littered with failures due to production bottlenecks, high costs, and biological challenges like spiders' cannibalistic nature.
Among the most prominent recent efforts:
Nexia Biotechnologies (Canada)- spent more than $110 million engineering goats to secrete spider silk proteins in milk, only to collapse before achieving viable scale. DuPont (USA)- DuPont invested $millions in bacterial expression, but abandoned the project, due to insolubility issues. BASF (USA)- cited insurmountable spinning challenges despite reportedly spending $50 million+ on R&D. Bolt Threads (USA)- raised over $400 million to produce “synthetic spider silk” through yeast fermentation but pivoted away from spider silk to focus on mycelium-based materials after commercialization hurdles. Spiber Inc. (Japan)- reportedly invested over $500 million developing fermentation-based “Brewed Protein,” but despite impressive progress, has yet to deliver material matching the strength, elasticity, and economics of natural spider silk. AMSilk (Germany)- backed by European venture funds and working with large consumer brands, yet still focused primarily on lab-scale quantities for niche applications. China- multiple state-backed research projects have explored transgenic silkworm and bacterial systems with varying success but remain pre-commercial. For all their financial firepower, these entities have faced a fundamental challenge: complex protein chain limits and other biological issues. Producing authentic, continuous spider silk fiber has proven far more complex, and costly, than anticipated.
Market Data 
Markets 
AI
